NOT MEDICAL ADVICE

FOXO4-DRI

Estimated Market Price
$159.99 $174.99
Based on verified supplier pricing for research-grade compounds
Senolytic peptide that selectively eliminates zombie cells. Disrupts senescent cell survival mechanisms to promote tissue rejuvenation and healthy aging.
How it works

Breaks the survival shield that keeps senescent ("zombie") cells alive by disrupting the FOXO4-p53 bond. This frees p53 to trigger self-destruction only in damaged senescent cells, leaving healthy cells untouched.

Longevity

Recovery & Longevity

What to Expect
Day 1 FOXO4-p53 disruption initiated; senescent cell targeting begins. Nothing noticeable yet; cellular cleanup just starting.
Days 2–3 Senescent cell apoptosis peaking; mild flu-like clearing possible. May feel mildly flu-ish as dead cells are cleared.
Week 1–2 Senescent cell burden reducing; tissue function improving. Skin may look fresher; energy slowly improving.
Week 3–4 Off-cycle recovery; healthy cell renewal filling cleared niches. Feeling more youthful; recovery and vitality increasing.
Month 2+ Repeat cycle; cumulative senolytic benefit with each round. Cumulative improvement; each cycle brings more rejuvenation.

Verified Suppliers

For research purposes only. These suppliers have been independently verified by PepSpace. We do not process sales directly.

PepSpace is not affiliated with any listed supplier
Protocol & Dosage
Typical Dosage 2–5 mg/kg SC
Administration Subcutaneous injection, Intravenous
Schedule Cycling: 3 consecutive days on, then 2–4 weeks off
Protocol Duration Cycling protocol (repeat every 4–6 weeks)
Half-Life Extended (D-amino acids resist proteolysis)
Side Effects & Safety
Tolerability Profile Moderate

Notable side effects likely; manageable with proper awareness

Common Side Effects

  • Injection site reactionmost users

Less Common

  • Fatigue (from senescent cell clearance)occasional
  • Headacheoccasional
  • Mild GI discomfortoccasional
  • Temporary flu-like feelingoccasional

Discontinue If

  • Signs of excessive cell death (severe fatigue, malaise)
  • Liver or kidney function changes (lab monitoring)
  • Severe allergic reaction

Contraindications

  • Active cancer or tumors
  • Severe immunodeficiency
  • Pregnancy or breastfeeding
  • Organ transplant recipients on immunosuppressants

Data note: Preclinical senolytic compound. Induces apoptosis in senescent cells — extremely limited human safety data. Use with caution.

Always consult a qualified healthcare professional before use. This information is for research reference only and does not constitute medical advice.

Ask about FOXO4-DRI
Send us a message

Call us
+1 (518) 327-4392
Business hours
Monday – Friday 9:00 AM – 6:00 PM EST
Saturday 10:00 AM – 2:00 PM EST
Sunday Closed

You can also reach us via or .

How to Apply

1

Gather

Peptide vial, BAC water, alcohol swabs, insulin syringe

2

Sanitize

Wipe tops of both vials with alcohol swabs

3

Draw

Pull 1–2 mL of BAC water into syringe

4

Add Water

Release water slowly along vial wall, not directly on powder

5

Swirl

Roll between palms until dissolved. Never shake.

6

Store

Refrigerate 2–8°C, use within 30 days

Frequently Asked Questions

Yes. Bacteriostatic water (BAC water) is required to reconstitute lyophilized (freeze-dried) peptides. It contains 0.9% benzyl alcohol which prevents bacterial growth, keeping your reconstituted peptide safe for multiple uses over up to 30 days.

Unreconstituted: store at -20°C (freezer) for long-term, or 2–8°C (fridge) for short-term. After reconstitution: always refrigerate at 2–8°C and use within 30 days. Keep away from direct sunlight.

Results vary by individual and protocol. In research settings, measurable effects are typically observed within 1–4 weeks depending on the specific peptide, dosage, and application. Consult a qualified professional for guidance.

Verified suppliers typically include a full third-party COA verifying purity (99%+), identity, and sterility. We recommend only sourcing from vendors that provide batch-specific testing data.

We list verified suppliers above that have been independently reviewed for product quality, testing transparency, and shipping reliability. Always verify COA data before sourcing.

Compound Profile

Scientific data & classification for FOXO4-DRI

Also Known As FOXO4-DRI, FOXO4-D-Retro-Inverso
Classification D-Retro-Inverso Peptide · Senolytic
Sequence D-retro-inverso peptide (~33 aa, all D-amino acids, reversed sequence)
Molecular Formula Peptide (~3.7 kDa)
Molecular Weight ~3,700 Da
CAS Number N/A
Half-Life Extended (D-amino acids resist proteolysis)
Origin Synthetic D-retro-inverso peptide designed by Erasmus University
Administration Subcutaneous injection, Intravenous
Status Research compound - preclinical
Mechanism of Action Breaks the survival shield that keeps senescent ("zombie") cells alive by disrupting the FOXO4-p53 bond. This frees p53 to trigger self-destruction only in damaged senescent cells, leaving healthy cells untouched.
Research Overview FOXO4-DRI is a D-retro-inverso peptide senolytic agent developed by Professor Peter de Keizer and colleagues at Erasmus University Medical Center in Rotterdam, first described in a landmark 2017 publication in the journal Cell. The compound represents an innovative application of the D-retro-inverso (DRI) peptide engineering strategy - the native FOXO4 peptide sequence is reversed (retro) and synthesized using D-amino acids (inverso), which results in a molecule that maintains the same spatial orientation of amino acid side chains as the original L-peptide (and therefore similar binding properties) but is highly resistant to proteolytic degradation by endogenous enzymes that have evolved to cleave L-peptide bonds. The scientific basis for FOXO4-DRI's senolytic activity lies in the biology of cellular senescence - when cells accumulate irreparable DNA damage or oncogenic stress, they enter a state of permanent growth arrest (senescence) that prevents potentially cancerous proliferation. However, senescent cells do not die but instead persist in tissues, secreting a complex mixture of pro-inflammatory cytokines, chemokines, matrix metalloproteinases, and growth factors collectively termed the senescence-associated secretory phenotype (SASP), which promotes chronic inflammation, tissue dysfunction, and age-related disease. A critical survival mechanism for senescent cells involves the transcription factor FOXO4, which accumulates in the nucleus of senescent cells and forms a complex with the tumor suppressor p53, sequestering p53 away from the mitochondria where it would trigger apoptosis. FOXO4-DRI disrupts this FOXO4-p53 interaction, releasing p53 to translocate to the mitochondria and activate the intrinsic apoptotic pathway specifically in senescent cells - healthy cells, which lack the elevated FOXO4-p53 nuclear interaction, are unaffected. In aged mice, FOXO4-DRI treatment neutralized chemotherapy-induced senescence, restored fitness, fur density, and renal function, and improved overall healthspan markers. The compound has generated tremendous excitement in the geroscience field as a potential therapeutic for age-related diseases.

Citations

Published findings on FOXO4-DRI from peer-reviewed journals.

Research Assistant
Hey, I'm the PepSpace research assistant. Ask me anything about peptides and I'll do my best to help.